A modified physiologic test for bronchopulmonary dysplasia: a clinical tool for weaning from CPAP and/or oxygen-therapy the premature babies?

Table 3 Patients characteristics, major morbidities and respiratory support at 36 weeks PMA

	Non tested infants (room air) (N 92)	Non tested infants (MV or FiO₂ > 0.3) (N 7)	Failed Group (N 6)	Passed Group (N 4)	P₁	P₂
GA (wks)	28.7 ± 2.4	25.9 ± 2.0	25.5 ± 1.6	26.0 ± 0.8	< 0.0001	0.36
BW (g)	995 ± 191	667 ± 274	673 ± 141	752 ± 245	< 0.0001	0.53
M/F	41/51	5/2	4/2	3/1	0.30	1
RDS	53 (58)	6 (86)	6 (100)	4 (100)	0.03	0.40
PDA	6 (6)	3 (43)	2 (33)	2 (50)	0.0007	1
IVH > 2^°	8 (9)	2 (28)	0 (0)	1 (25)	0.20	0.40
Sepsis	29 (31)	5 (71)	4 (67)	2 (50)	0.06	0.50
Survival	91 (99)	4 (57)	6 (100)	3 (75)	< 0.0001	0.40
Neonates on CPAP	0	1 (14)	0	1 (25)	0.0002	1
Baseline FiO₂	0.21 [0.21–0.21]	0.30 [0.21–0.50]	0.25 [0.23–0.27]	0.23 [0.21–0.23]	< 0.0001	0.01

Values are expressed as mean ± SD, median [range] or number (%)
P₁: comparison between the groups; P₂: comparison between the Failed and Passed groups
GA gestational age, BW birth weight, RDS respiratory distress syndrome, PDA patent ductus arteriosus surgically ligated, IVH intraventricular hemorrhage, FiO₂ Fraction of inspired oxygen, MV mechanical ventilation

ISSN: 1824-7288